TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21366599
Drug: Intranasal phototherapy
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal phototherapy (three times a week for 2 weeks)
Study: 21366599
Drug: Fexofenadine HCl
Normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine HCl (180 mg per day for 2 weeks)
Study: 19711095
Drug: Combined nebulized
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined nebulized bronchodilators (BD)
Study: 14644068
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of dexamethasone (DEX)
Study: 11443153
Drug: GH (genotropin
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH (genotropin 4 IU/m(2).day) and GnRHa (triptorelin, 3.75 mg/28 days)
Study: 8148931
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg dexfenfluramine (DF) twice daily
Study: 8148931
Drug: 20 mg/200
Normalized name: niCARdipine 20 mg/200 mL-D4.8% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/200 mg ephedrine/caffeine (EC) three times a day
Study: 23402525
Drug: Minimal Psychological
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal Psychological Intervention (MPI) administered by trained nurses in cognitive behavioural therapy and self-management.
Study: 18784526
Drug: 0.5% sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% sterile solution of metronidazole (2 mL, 10 mg) incorporated in the sinus bone graft
Study: 16898076
Drug: New retard
Approvals — FDA: no, EMA: no, PMDA: no
Description: New retard tablet formulation (240mg oral)
Study: 16898076
Drug: Standard retard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard retard tablet formulation (240mg oral)
Study: 16898076
Drug: Intravenous dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dose (5mg)
Study: 14597782
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (3 mg in 10 ml saline)
Study: 11070572
Drug: Mebeverine hydrochloride
Normalized name: Mebeverine hydrochloride
DrugBank: Mebeverine (DB12554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebeverine hydrochloride 135 mg t.i.d. (Colofac)
Study: 11070572
Drug: Mebeverine hydrochloride
Normalized name: Mebeverine hydrochloride
DrugBank: Mebeverine (DB12554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebeverine hydrochloride 200 mg b.i.d. (Colofac MR)
Study: 1450803
Drug: Intralesional corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional corticosteroid injection (methylprednisolone and lignocaine)
Study: 1450803
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection (lignocaine alone)
Study: 6363095
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg of MA
Study: 6363095
Drug: 180 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg of MA
Study: 6363095
Drug: 270 mg
Normalized name: leucine 270 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 270 mg of MA
Study: 26884559
Drug: Doxorubicin, bleomycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by ifosfamide-containing salvage treatment and stem-cell transplantation for PET2-positive patients
Study: 20871804
Drug: Problem-solving therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving therapy in home care (PST-HC)
Study: 17617743
Drug: DTwP-HepB-Hib vaccine
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTwP-HepB-Hib vaccine administered at 0, 4, and 8 weeks
Study: 17617743
Drug: DTwP-HepB-Hib vaccine
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTwP-HepB-Hib vaccine
Study: 8654899
Drug: Ineraid cochlear
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ineraid cochlear implant users
Study: 387001
Drug: Luteinizing hormone-releasing
Normalized name: (6-D-Tryptophan)luteinizing hormone-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteinizing hormone-releasing hormone (LRH, 500 micrograms, intramuscularly injected)
Study: 30986809
Drug: CDK4/6 inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDK4/6 inhibitors (palbociclib or ribociclib) in combination with cetuximab
Study: 30986809
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of palbociclib/cetuximab
Study: 30986809
Drug: Combination therapies
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapies (CDK4/6 inhibitors with other agents)
Study: 23792937
Drug: Cholecalciferol and
Normalized name: Cholecalciferol and retinol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol and Ergocalciferol (both treatments)
Study: 21035237
Drug: Dexamethasone 4
Normalized name: dexamethasone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 4 mg submucosally
Study: 21035237
Drug: Dexamethasone 4
Normalized name: dexamethasone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 4 mg intramuscularly
Study: 15135483
Drug: G17DT antibodies
Normalized name: G17DT
DrugBank: G17DT Immunogen (DB04914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G17DT antibodies
Study: 11466984
Drug: Presumed non-effective
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presumed non-effective reflexological treatment (Group A)
Study: 11466984
Drug: Presumed effective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presumed effective reflexological treatment (Group B)
Study: 11466984
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment - only observation (Group C)
Study: 9728931
Drug: LPONL(G)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPONL(G)
Study: 4448876
Drug: Modeling treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modeling treatment
Study: 25887238
Drug: Multifaceted educational
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifaceted educational program for nursing home care staff on assessment and treatment of fecal incontinence
Study: 23190342
Drug: IncobotulinumtoxinA (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: IncobotulinumtoxinA (20 U per cycle, up to eight treatment cycles, treatment interval at least 85 days)
Study: 22191131
Drug: Vacuum Assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vacuum Assisted Closure (VAC) therapy
Study: 19656069
Drug: Mefloquine (MQ)
DrugBank: Mefloquine (DB00358)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefloquine (MQ) 15 mg/kg in a single intake twice during pregnancy
Study: 19656069
Drug: Sulfadoxine-pyrimethamine (SP)
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-pyrimethamine (SP) 1500 mg sulfadoxine and 75 mg pyrimethamine in a single intake twice during pregnancy
Study: 16291984
Drug: Sildenafil 20
Normalized name: sildenafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 20 mg
Study: 30383134
Drug: Sildenafil 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 40 mg
Study: 30383134
Drug: Sildenafil 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 80 mg
Study: 12920042
Drug: Desmopressin (DDAVP)
Normalized name: desmopressin Injection [DDAVP]
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Desmopressin (DDAVP) infusion
Study: 12920042
Drug: Physiologic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic saline infusion (placebo)
Study: 10839552
Drug: Antibiotics (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (dosage and duration not specified)
Study: 10839552
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drugs, alpha-blocking agents, anticholinergic agents or other therapies
Study: 3533264
Drug: Captopril 150
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril 150 mg daily
Study: 3533264
Drug: Methyldopa 750
Normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyldopa 750 mg daily
Study: 25038985
Drug: High-frequency deep
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-frequency deep TMS treatment
Study: 25038985
Drug: Low-frequency deep
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency deep TMS treatment
Study: 22858177
Drug: Revaprazan 200
Normalized name: Revaprazan
DrugBank: Revaprazan (DB16308)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revaprazan 200 mg once daily for 7 days
Study: 22858177
Drug: Itopride 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itopride 50 mg TID for 7 days
Study: 22858177
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of revaprazan and itopride
Study: 20133068
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (500 μg of sodium selenite during RT and 300 μg on non-RT days)
Study: 10368794
Drug: Oral DHEAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral DHEAS (50 mg/day)
Study: 10368794
Drug: Oral DHEAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral DHEAS (50 mg/day) + transdermal estradiol (50 micrograms/patch)
Study: 1877335
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control) for 31/2 weeks
Study: 7174915
Drug: Topical 8‐methoxypsoralen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 8‐methoxypsoralen (8‐MOP) 0.1%
Study: 7174915
Drug: Topical 8‐methoxypsoralen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 8‐methoxypsoralen (8‐MOP) 0.5%
Study: 7174915
Drug: Topical 8‐methoxypsoralen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 8‐methoxypsoralen (8‐MOP) 1%
Study: 7174915
Drug: Topical 8‐methoxypsoralen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 8‐methoxypsoralen (8‐MOP)
Study: 25431880
Drug: Control (alternative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (alternative meal, e.g., chicken, pork, or beef three times per week during the same period)
Study: 22260297
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine 1.5 mg/kg followed by a continuous infusion of 2 mg/kg/h
Study: 17352868
Drug: Chaige Qingre
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chaige Qingre Granule (6 g, 4 times daily for 3 days)
Study: 17352868
Drug: Fufang Shuanghua
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fufang Shuanghua Granule (6 g, 4 times daily for 3 days)
Study: 12885350
Drug: Vaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination with 10(7) or 10(8) irradiated CD80-modified tumor cells with GM-CSF or BCG, three times at 2-week intervals and then monthly until progressive disease developed.
Study: 12885350
Drug: Vaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination with 10(8) tumor cell dose.
Study: 9346678
Drug: ganciclovir (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: ganciclovir (6 mg/kg/day intravenously for a total of 100 days)
Study: 9346678
Drug: acyclovir (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: acyclovir (10 mg/kg every 8 hours intravenously until discharged and then 800 mg orally every 6 hours for a total of 100 days)
Study: 30382352
Drug: Remotiv 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remotiv 250 (250 mg of H. perforatum)
Study: 30382352
Drug: Remotiv 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remotiv 500 (500 mg of H. perforatum)
Study: 26358764
Drug: Topical combination
Normalized name: soap TOPICAL COMBINATION PACKAGE (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical combination of calcipotriol and betamethasone (Group A)
Study: 18574489
Drug: Regular passive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular passive movements administered for 10 min, 10 times a week for 6 months.
Study: 8633581
Drug: Chloroquine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (500 mg/day)
Study: 29326330
Drug: Multi-component intervention
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-component intervention including individualised care/action plans and telephone consults (12-weekly then 9-monthly)
Study: 27279511
Drug: TAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP block using 20 mL 0.25% bupivacaine
Study: 27279511
Drug: Control block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control block using 20 mL 0.9% Sodium chloride
Study: 19578163
Drug: Pravastatin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin therapy (40 mg/day)
Study: 16173357
Drug: Dialectical Behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behavior Therapy
Study: 16173357
Drug: Trauma Model
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma Model Therapy
Study: 9885787
Drug: CCK-4 injection
Normalized name: CCK-8
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CCK-4 injection during the follicular phase
Study: 9885787
Drug: CCK-4 injection
Normalized name: CCK-8
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CCK-4 injection during the luteal phase
Study: 9885787
Drug: CCK-4 injection
Normalized name: CCK-8
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CCK-4 injection (both phases)
Study: 7726308
Drug: Lactate infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate infusion with 0.9% sodium chloride
Study: 7726308
Drug: Lactate infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate infusion with 5% dextrose in water
Study: 7726308
Drug: Both infusions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both infusions
Study: 2174121
Drug: MK-571 (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-571 (160 mg)
Study: 30992301
Drug: Ixazomib in
Normalized name: Product containing ixazomib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib in combination with MEC (mitoxantrone, etoposide, cytarabine)
Study: 28033159
Drug: Dexamethasone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1 mL of 0.4% dexamethasone)
Study: 28033159
Drug: Control (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (1 mL of saline)
Study: 25450293
Drug: Leptin treatment
Normalized name: leptin
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leptin treatment in cultured endometrial cells (Ishikawa cells)
Study: 19923847
Drug: Extended-interval dosing
Normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-interval dosing (triptorelin 3.75 mg by intramuscular injection every 6 weeks for a total of 4 doses)
Study: 19923847
Drug: Conventional dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dosing (1 injection every 4 weeks for a total of 6 doses)
Study: 17427818
Drug: Self-etching, self-priming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-etching, self-priming dentin bonding agent
Study: 9475525
Drug: No photodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No photodynamic therapy
Study: 7620004
Drug: Piperacillin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin (4 g) three times daily for up to 7 days
Study: 7620004
Drug: Placebo three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo three times daily for up to 7 days
Study: 2244441
Drug: Bupivacaine-epinephrine mixture
Normalized name: bupivacaine / epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine-epinephrine mixture (0.5% bupivacaine, 5 micrograms/ml epinephrine)
Study: 31332549
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation plus routine antihistamine medication (cetirizine)
Study: 29258261
Drug: Oligofructose (Orafti®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligofructose (Orafti® P95) at 15 g/day
Study: 29258261
Drug: Oligofructose (Orafti®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligofructose (Orafti® P95) at 10 g/day
Study: 21715514
Drug: Cholecalciferol (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (2000 IU once daily)
Study: 18953578
Drug: Physical Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Training plus Cognitive-Behavioral Therapy (PT + CBT)
Study: 11190013
Drug: diclofenac 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac 0.1% ophthalmic solution
Study: 10193219
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg.kg‐1
Study: 10193219
Drug: Vecuronium 0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.08 mg.kg‐1
Study: 24927068
Drug: Topical agent
Normalized name: topical agent combination no.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical agent (Skinceuticals Body Tightening Concentrate) applied twice daily to one designated thigh/buttock
Study: 24927068
Drug: Radiofrequency (RF)
Normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiofrequency (RF) device (Alma Accent) treatment
Study: 24927068
Drug: Topical agent
Normalized name: topical agent combination no.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical agent (Skinceuticals Body Tightening Concentrate)
Study: 22345330
Drug: Milk-based cornstarch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk-based cornstarch porridge fortified with 10 mg elemental iron (FeSO4), daily, during 14 weeks
Study: 18755342
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) or enoxaparin plus a glycoprotein (GP) IIb/IIIa inhibitor
Study: 18755342
Drug: Bivalirudin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin plus a GP IIb/IIIa inhibitor
Study: 10102851
Drug: Best supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best supportive care (standard management and treatment for breathlessness, breathing assessments)
Study: 568293
Drug: Paracetamol (N-acetyl-p-amino-phenol)
Normalized name: N-acetyl-p-aminophenol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol (N-acetyl-p-amino-phenol)
Study: 30183710
Drug: Internet-based stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based stress management program ('I'm managing my stress'), composed of four sessions based on cognitive-behavioral therapy.
Study: 27732819
Drug: Current standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current standard of care plus ZMapp (50 mg/kg, administered every third day)
Study: 18622147
Drug: peg‐interferon plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: peg‐interferon plus ribavirin combined therapy
Study: 16026361
Drug: Pioglitazone (30‐45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30‐45 mg/day, n = 38)
Study: 16026361
Drug: Metformin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (750 mg/day, n = 39)
Study: 16026361
Drug: Glimepiride (1.0‐2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (1.0‐2.0 mg/day, n = 37)
Study: 8543404
Drug: 3 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/m2 AS101 combined with carboplatin and VP-16
Study: 19168237
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion of acetylcholine (ACh)
Study: 17571296
Drug: Preoperative intraperitoneal
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative intraperitoneal local anaesthesia (50 ml 0.5 per cent lidocaine)
Study: 17571296
Drug: Postoperative intraperitoneal
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative intraperitoneal local anaesthesia (50 ml 0.5 per cent lidocaine)
Study: 17571296
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution (50 ml 0.9 per cent saline)
Study: 16135164
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg terbutaline
Study: 16135164
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg terbutaline after withdrawal from beta(2) agonists
Study: 7550179
Drug: Rifabutin 300
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifabutin 300 mg/day
Study: 2029659
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (2000 IU 12 hours prior to surgery) and Vitamin C (2 g on the day of operation)
Study: 2029659
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no vitamin E or C treatment)
Study: 6135725
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose propranolol (22 +/- 4 mg four times daily)
Study: 31573893
Drug: Sofosbuvir 400
Normalized name: sofosbuvir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir 400 mg/Daclatasvir 60 mg
Study: 31573893
Drug: Sofosbuvir 400
Normalized name: sofosbuvir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir 400 mg/Ledipasvir 90 mg
Study: 30942258
Drug: Miltefosine 1.3‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miltefosine 1.3‐2 mg/kg/day for 28 days
Study: 30942258
Drug: Meglumine antimoniate
Normalized name: meglumine antimoniate
DrugBank: Meglumine antimoniate (DB13732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meglumine antimoniate (N‐MA) 20 mg SbV/kg/day for 30 days
Study: 27194863
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CHX (0.12%) and HVE
Study: 9302369
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for the first 6 months followed by GH administration for the next 6 months
Study: 8287572
Drug: Suramin i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suramin i.v. / Melarsoprol (during treatment)